摘要
目的:探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中核苷酸还原酶M1(RRM1)的表达水平及其与NSCLC患者病情进展及预后的关系。方法:免疫组织化学法检测60例晚期NSCLC患者肺组织中RRM1蛋白表达水平,并与患者的临床特征及预后关系进行分析。结果:RRM1的表达与性别有统计学差异(P<0.05);与年龄、组织学类型及分期均无统计学差异(P>0.05)。在对生存期的分析中发现RRM1低表达组的中位生存期(18个月)及无疾病进展期(6个月)均明显长于高表达组(13个月,4个月)(P<0.05),1年生存率(69.2%)及2年生存率(23.1%)均高于高表达组(58.8%,3%)(P<0.05)。结论:晚期非小细胞肺癌组织中RRM1低表达的患者比高表达患者有更长的中位生存期及无疾病进展生存期。因此,RRM1表达水平可作为晚期NSCLC的一个重要的预测预后的标志物。
Objective： To investigate the expression level of ribonucleotide reductase M1 （RRM1） and the rela- tionship with NSCLC patients progress and prognosis in advanced non -small cell lung cancer（NSCLC）. Methods： Tumor samples obtained from 60 patients with advanced NSCLC were collected to investigate the expression level of RRM1 by immunohistochemical methods. Relationships between the expression and clinical characters, prognostic of patients with advanced NSCLC were analyzed. Results：There was difference between RRM 1 expression and gender （P 〈 0.05 ）, while there was no correlation between RRM 1 expression and age, histologic type and TNM stage （P 〉 0.05 ）. Low expression group of RRM1 had longer overall survival （18 months, 13 months）, longer no disease pro- gression period（6 months,4 months）. There were higher 1 - year survival rate（69.2% ,58.8% ） and 2 - year surviv- al rate （23.1% ,3 % ） than over expression group of RRM1 （ P 〈 0.05 ）. Conclusion： The patients of advanced non - small cell lung cancer with low RRM1 expression level had longer survival time. RRM1 expression level was an impor- tant prognostic factor for the patients in advanced non - small cell lung cancer.
出处
《现代肿瘤医学》
CAS
2013年第3期518-520,共3页
Journal of Modern Oncology
基金
云南省教育厅科学基金项目(编号:2010Y183)
